EGFR and head and neck squamous cell carcinoma: In another study, Ferris reported that JAK2/STAT1 signaling was involved in EGFR-mediated immune evasion in HNSCC and that therapies targeting this signaling pathway may be beneficial for blocking PD-L1 upregulation in HNSCC (72).